introduction: involvement of the skeleton can cause an excruciating pain in two-thirds of terminal patients with a history of malignancy. due to several limitations of other therapies, such as analgesics, bisphosphonates, chemotherapy, hormonal therapy and external beam radiotherapy; bone-seeking radiopharmaceuticals have an important role in palliation of pain from bone metastases. although th...

Targeted radionuclide therapy is one of the most intensively developing directions of nuclear medicine. Unlike conventional external beam therapy, the targeted radionuclide therapy causes less collateral damage to normal tissues and allows targeted drug delivery to a clinically diagnosed neoplastic malformations, as well as metastasized cells and cellular clusters, thus providing systemic thera...

OBJECTIVE This continuing education article reviews radionuclide bone therapy agents that are available commercially and introduces agents that are being evaluated for future use. Currently these agents are used to provide pain palliation from metastases to bone. Future applications may include adjuvant therapy to surgery or external beam treatment. After reading this paper, the reader should b...

Targeted radiotherapy is an evolving and promising modality of cancer treatment. The killing of cancer cells is achieved with the use of biological vectors and appropriate radionuclides. Among the many advantages of this approach are its selectiveness in delivering the radiation to the target, relatively less severe and infrequent side effects, and the possibility of assessing the uptake by the...

On their plasma membranes, cells express receptor proteins with high affinity for regulatory peptides, such as somatostatin. Changes in the density of these receptors during disease, for example, overexpression in many tumors, provide the basis for new imaging methods. The first peptide analogues successfully applied for visualization of receptor-positive tumors were radiolabeled somatostatin a...

Background: In internal radiation therapy of cancer, optimal targeting ligand and type therapeutic radionuclide must be considered carefully for effective treatment. addition, nuclide may vary depending on diverse parameters characterizing the tumor. Thus, use in various cancers, there is a need development carrier that can firmly bind to variety nuclides. Here we introduce biocompatible iron o...